Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics, Incorporated is asking stockholders to vote at its May 27, 2026 annual meeting on board elections, equity incentives, auditor ratification and executive pay. Three Class I directors are up for re-election to serve until the 2029 annual meeting.
Stockholders are asked to approve an amendment to the 2015 Employee Stock Purchase Plan adding 1,000,000 shares, raising the total reserve to 2,459,879 shares, which the company estimates would increase ESPP-related dilution from about 1.2% to about 2.0%. The agenda also includes ratifying Ernst & Young as independent auditor for 2026 and an advisory “say-on-pay” vote on 2025 compensation for named executive officers.
CYTOKINETICS INC director Nancy Wysenski received a grant of 95 shares of Common Stock valued at $65.37 per share. The award was made as part of the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this compensation-related acquisition, she directly owns 31,066 shares of Common Stock.
Cytokinetics director Wendell Wierenga received a stock grant of 95 shares of Common Stock as part of the company’s Director Equity in Lieu of Cash Retainer Program. The shares are fully vested, meaning they are not subject to additional service conditions.
Following this equity award, Wierenga directly holds a total of 32,637 shares of Cytokinetics Common Stock. This Form 4 reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director Edward M. Kaye, MD received 191 shares of Common Stock as an equity grant. The shares were granted under the Director Equity in Lieu of Cash Retainer Program at a reference price of $65.37 per share and are fully vested. Following this compensation-related award, he directly holds 10,365 shares of Cytokinetics common stock.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director John T. Henderson received 325 shares of Common Stock as equity compensation instead of a cash retainer. The award was granted under the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this grant, he directly holds 75,237 shares, with an additional 83 shares held indirectly through his spouse.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Robert Arthur Harrington received a grant of 191 shares of Common Stock as equity compensation. The shares were granted under a Director Equity in Lieu of Cash Retainer Program and are fully vested, meaning he owns them outright. Following this award, he directly holds 18,930 shares of CYTOKINETICS INC common stock.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director James M. Daly received 191 shares of common stock as a fully vested equity award under the Director Equity in Lieu of Cash Retainer Program. The shares were valued at $65.37 each on the grant date. After this award, Daly directly holds 388 CYTK common shares.
CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock. As EVP and Chief Commercial Officer, he sold 7,449 shares of Common Stock at a price of $66.02 per share. Following this transaction, he directly holds 58,555 shares of CYTOKINETICS INC Common Stock.
Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of common stock. He sold 7,500 shares of Cytokinetics common stock at $65.38 per share on April 15, 2026.
After this transaction, Blum directly owns 415,330 shares of Cytokinetics common stock. He also has indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.